Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study
Dusan Kotasek(Centre for Cancer Biology), Timothy Price(Basil Hetzel Institute), Adeboye H. Adewoye(Amgen (United States)), Jayesh Desai(Peter MacCallum Cancer Centre), Niall C. Tebbutt(Austin Health), Jessica Johnson(University of North Carolina at Chapel Hill), Sheryl McCoy(Amgen (United States)), Lillian L. Siu(University Health Network), Yu‐Nien Sun(Janssen (United States)), Stephen Welch(Cancer Care Ontario)
Cited by 9
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
De novo mutations in schizophrenia implicate synaptic networks
|Nature|2014|1.7k